South Korean AI Firms Secure Global Healthcare Contracts
Diagnostic AI companies are expanding their footprint across national medical screening programs globally.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you trust that integrating AI into your local healthcare screening improves the accuracy of results?
South Korean AI healthcare firms are increasingly integrating diagnostic software into national screening programs worldwide as of September 2026. These platforms are designed to analyze medical images to detect conditions like cancer, helping nations manage rising healthcare costs.
Why it matters
Governments are turning to AI technologies to alleviate the workload of medical professionals and improve diagnostic accuracy in public health sectors. This deployment serves as a key strategy to address the growing operational demands on national healthcare systems.
Coreline Soft secured 77 new contracts in Germany through July 2026, while 3billion reported 4.9 billion Korean won in overseas sales for the first half of the year. The global medical imaging AI market is projected to reach $28.4 billion by 2032.
The players
Lunit
This South Korean medical AI firm develops diagnostic software used for breast cancer screening programs.
Coreline Soft
This technology company specializes in AI platforms for thoracic disease diagnosis and lung cancer screening.
Vuno
This AI provider offers deep learning-based diagnostic solutions for various medical conditions including eye-related diseases.
Aidot
This organization develops AI-powered medical devices used in cervical cancer and other diagnostic screening networks.
3billion
This company focuses on genomic screening systems and genetic testing technologies for newborn populations.
The details
Companies including Lunit, Coreline Soft, and Vuno are deploying AI as second readers for clinicians across international sites such as Malta, Australia, and China. These integrations rely on clinical evidence gathered in hospital settings to scale diagnostic support for public screening initiatives.
Timeline
Lunit began supplying AI to Capio St. Göran Hospital in 2023.
Germany integrated low-dose lung cancer screenings into insurance in April 2026.
Australia reported screening 100,000 people for lung cancer in June 2026.
Coreline Soft reached 77 contracts in Germany by July 2026.
Vuno connected its Fundus AI to Chinese medical institutions in September 2026.
Market Landscape
The shift toward AI-integrated public health reflects a broader trend of leveraging automated diagnostics to reach the projected $28.4 billion global medical imaging AI market by 2032. This expansion positions South Korean software providers as critical components in national healthcare infrastructure against rising cost pressures.
Patients in participating regions may experience faster diagnostic results and improved detection rates for conditions like cancer during routine screenings. These advancements aim to optimize medical resource allocation, potentially reducing wait times for clinical interpretation.
The takeaway
The adoption of AI in public screening programs demonstrates a scalable model for countries looking to improve diagnostic efficiency. As technology matures, patients can expect more consistent and rapid analysis of their medical imaging results.
What happens next
The UK government plans to complete the deployment of AI-based chest X-ray reading tools across all NHS hospitals in England by 2029.
Further reading
Learn more about the latest innovations in the Healthcare sector.
Live Poll
Do you trust that integrating AI into your local healthcare screening improves the accuracy of results?
